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A large body of evidence implicates a central role for mito-
chondrial dysfunction in the pathogenesis of Parkinson’s
disease (PD), although the precise causes of mitochondrial
dysfunction in PD remain to be determined. Mitochondrial
complex I activity is impaired in the substantia nigra at
early stages in PD. This complex I dysfunction appears not
to be simply a consequence of neurodegeneration as toxins
that inhibit mitochondrial complex I can reproduce many
of the key pathological features of PD in animal models.
Several genetic causes of PD have been linked directly or
indirectly to mitochondrial function, and thus a convergence
of data highlights the role of mitochondrial dysfunction
in PD. This special issue now explores several key issues
relating to the role of mitochondrial dysfunction in PD,
potential causes and consequences of the dysfunction, and
implications regarding neuroprotective strategies.
TheﬁrstpaperbyA.H.V.SchapiraandM.Geggprovides
a brief but broad overview of mitochondrial dysfunction in
PD. In addition to a discussion of parkinsonism associated
with mutations in mitochondrial DNA (mtDNA) poly-
merase gamma (POLG), links to abnormal mitochondrial
dysfunction are reported for several genetic causes of PD,
including PINK1, Parkin, DJ-1, alpha-synuclein, and HtrA2.
The role of PINK1, Parkin, and DJ-1 in the degradation of
dysfunctional mitochondria (mitophagy) is discussed also.
The second paper by J. Clark, Y. Dai, and D. K. Simon
reviews data regarding the potential contribution of mtDNA
mutations to PD. This review brieﬂy discusses evidence
for mitochondrial dysfunction in PD, as well as data from
cytoplasmic hybrid (“cybrid”) cell lines that implicate a
role for mtDNA mutations as a cause of the mitochondrial
dysfunction. The paper then focuses primarily on data
suggesting a role for somatic mtDNA mutations. The
signiﬁcance to PD of data from the POLG “mutator” mouse
model of premature aging also is discussed, including the
issue of point mutations versus large deletions.
The third article by C. T. Chu reviews the evidence for
altered autophagy or mitophagy in the major genetic models
of parkinsonian neurodegeneration, α-synuclein, leucine-
rich repeat kinase 2 (LRRK2), Parkin, PTEN-induced kinase
1 (PINK1), and DJ-1. In recent years, autophagy dysregula-
tion has been implicated widely in toxic/environmental and
geneticapproachestostudyingPDpathogenesis.Diminished
autolysosomal surveillance leads to alterations in mitochon-
drial oxygen utilization or calcium buﬀering. Interactions
of two recessive PD-linked proteins, PINK1 and Parkin,
contribute to a mechanism by which dissipation of the inner
mitochondrial membrane potential triggers selective mito-
chondrial targeting for autophagy. These data are discussed
in the context of emerging knowledge in the basic regulation
of autophagy induction and cargo targeting, with discussion
of neuron-speciﬁc mechanisms that may diﬀer from those
observed in other cell types.
The fourth article by A. Rakovic et al. is a research article
in which tandem aﬃnity puriﬁcation and mass spectrometry
were utilized to conﬁrm interactions of PINK1 with HSP90
and CDC37 molecular chaperones, while highlighting 4
mitochondrially localized proteins that may interact with
PINK1. Although no changes in protein expression were
observed in control versus PINK1 mutant ﬁbroblast lines,
mutations in the LRPPRC gene encoding one of these pro-
teinscauseaformofLeighsyndrome,acytochromecoxidase2 Parkinson’s Disease
deﬁciency that results in childhood brain infarcts. Further
studies of PINK1 regulation of mitochondrial function may
wellrevealfunctionsbeyondthoselinkedtoParkin-regulated
mitophagy.
The ﬁfth paper by P. C. Keane et al. reviews mecha-
nismsthroughwhichmitochondrialdysfunctionmayimpair
function and induce neurodegeneration in PD, as well as
mediate the adverse consequences of gene mutations known
to associate with Mendelian PD. Relationships between
mitochondria and oxidative stress, cell calcium homeostasis,
dopaminemetabolism,andLewybodiesareaddressed.What
we have learned over the years regarding PD-associated
toxins, as well as mutations in genes such as Parkin, Pink1,
alpha synuclein, and DJ1, are discussed from the perspective
of mitochondria and cell bioenergetics. Overall, this review
makes a compelling case for why mitochondria should be
considered to play a key role in both PD etiology and
physiology.
The sixth paper, a review by K. U. Tufekci et al., focuses
on compensatory transcriptional responses to oxidative
stress mediated by the Nrf2 transcription factor. Through
the electrophile response element, Nrf2 participates in
upregulation of antioxidant and anti-inﬂammatory genes
and aﬀects mitochondrial biogenesis. Interestingly, the
survival-death outcome in injuries associated with increased
mitophagy may be governed by whether or not there
are concurrent deﬁciencies in mitochondrial biogenesis, as
observed in a chronic culture model of MPP+ intoxication
(Zhu et al., Cell Death and Disease, 2012 May 24; 3:e312.
doi: 10.1038/cddis.2012.46). Given recent data implicating
crosstalk between autophagy and Nrf2, Nrf2 may represent a
promising therapeutic target addressing several mechanisms
implicated in PD pathogenesis.
In the seventh paper, D. M. Ardu´ ıno et al. address
the fact that, in addition to mitophagy, other aspects of
mitochondrialdynamicshavebeenimplicatedinPDmodels.
These authors review recent studies implicating changes in
mitochondrial ﬁssion and fusion, mitochondrial biogenesis,
degradation, and transport along microtubules in the major
genetic models of PD. A model whereby deﬁcits in mito-
chondrial bioenergetics may underlie each of these changes
is proposed, although several PD genes may also show direct
eﬀects on mitochondrial transport or mitochondrial ﬁssion.
T h ee i g h t hp a p e rb yA .R .E s t e v e se ta l .p r o v i d e sab r o a d
review of evidence for mitochondrial dysfunction in PD as
wellaspotentialcausesandconsequencesofthisdysfunction.
The topics include oxidative stress, calcium homeostasis,
the NAD+/NADH ratio, autophagy, and mitophagy. The
“mitochondrial cascade” hypothesis is discussed in which
each of these mechanisms ultimately contributes to alpha-
synuclein aggregation followed by neuronal death.
Finally, the ninth paper is a review by R. B. Mounsey
and P. Teismann that provides a historical overview of data
implicating mitochondria in PD pathogenesis. This paper
spans early data from idiopathic PD through consideration
of the MPTP, rotenone and 6-hydroxydopamine models,
to recent work exploring how genetic mutations inﬂuence
mitochondrial activity. The preclinical data underlying sev-
eral potential mitochondrially targeted therapies are dis-
cussed.
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